C.ChiaL
3050 (median, 37) years of age
Potential Risks and Considerations Even setting aside regulatory status, any consideration of growth hormone stimulating compounds requires awareness of potential risks that appear in the clinical and safety literature: Water retention and edema Joint pain (arthralgia), which is a known side effect of GH elevation Potential impact on insulin sensitivity GH affects glucose metabolism Theoretical concerns about stimulating GH in individuals with undiagnosed malignancies (GH is a growth factor) Unknown long-term effects from extended use in healthy adults Quality and purity concerns when obtained outside regulated pharmaceutical channels These considerations underscore why any decision regarding peptide therapy must involve a physician who can review individual medical history, contraindications, and current evidence not a wellness clinic, online pharmacy, or influencer recommendation
With so much information about different nutrients and supplements, why should you care about glutathione
Thyroid dysfunction can mimic side effects of GLP-1 therapy, complicating clinical assessment
March 1: The FDA on Friday granted full approval of J&Js Rybrevant in combination with chemotherapy as a first-line treatment for patients with non-small cell lung cancer (NSCLC) EGFR exon 20 insertion mutations, the company announced
